Robert L. De Jager

785 total citations
13 papers, 462 citations indexed

About

Robert L. De Jager is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Robert L. De Jager has authored 13 papers receiving a total of 462 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 5 papers in Molecular Biology and 3 papers in Epidemiology. Recurrent topics in Robert L. De Jager's work include Cancer therapeutics and mechanisms (5 papers), Pancreatic and Hepatic Oncology Research (4 papers) and Cancer Treatment and Pharmacology (4 papers). Robert L. De Jager is often cited by papers focused on Cancer therapeutics and mechanisms (5 papers), Pancreatic and Hepatic Oncology Research (4 papers) and Cancer Treatment and Pharmacology (4 papers). Robert L. De Jager collaborates with scholars based in United States, Russia and Japan. Robert L. De Jager's co-authors include Herbert I. Hurwitz, Manuel Modiano, N. Simon Tchekmedyian, Eileen M. O’Reilly, Ghassan K. Abou‐Alfa, Graydon Harker, S. Gail Eckhardt, Richard Létourneau, Kevie Feit and S. Gail Eckhardt and has published in prestigious journals such as Journal of Clinical Oncology, Anti-Cancer Drugs and PubMed.

In The Last Decade

Robert L. De Jager

12 papers receiving 449 citations

Peers

Robert L. De Jager
Kevie Feit United States
Henry J. Durivage United States
Federico Castiglione Italy
G. Stathopoulos Greece
Jianling Zou China
Yasuhiro Arakawa Japan
Monica Capozzi Italy
C. Louvet France
Eleonora Zaccarelli Italy
Kevie Feit United States
Robert L. De Jager
Citations per year, relative to Robert L. De Jager Robert L. De Jager (= 1×) peers Kevie Feit

Countries citing papers authored by Robert L. De Jager

Since Specialization
Citations

This map shows the geographic impact of Robert L. De Jager's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert L. De Jager with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert L. De Jager more than expected).

Fields of papers citing papers by Robert L. De Jager

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert L. De Jager. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert L. De Jager. The network helps show where Robert L. De Jager may publish in the future.

Co-authorship network of co-authors of Robert L. De Jager

This figure shows the co-authorship network connecting the top 25 collaborators of Robert L. De Jager. A scholar is included among the top collaborators of Robert L. De Jager based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert L. De Jager. Robert L. De Jager is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
2.
Ciuleanu, Tudor–Eliade, Y. Demidchik, С. В. Орлов, et al.. (2010). Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy.. Journal of Clinical Oncology. 28(15_suppl). 7002–7002. 35 indexed citations
3.
Jager, Robert L. De, et al.. (2009). Results of a phase II study of picoplatin with docetaxel and prednisone in first-line treatment of castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 27(15_suppl). 5140–5140. 3 indexed citations
4.
Abou‐Alfa, Ghassan K., Richard Létourneau, Graydon Harker, et al.. (2006). Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic Cancer. Journal of Clinical Oncology. 24(27). 4441–4447. 227 indexed citations
5.
Reilly, E. M. O', G.K. Abou-Alfa, W G Harker, et al.. (2004). A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC). Journal of Clinical Oncology. 22(14_suppl). 4006–4006. 53 indexed citations
6.
Reilly, E. M. O', et al.. (2004). A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC). Journal of Clinical Oncology. 22(14_suppl). 4006–4006. 17 indexed citations
7.
Garrison, Mitchell, Lisa A. Hammond, Charles E. Geyer, et al.. (2003). A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.. PubMed. 9(7). 2527–37. 14 indexed citations
8.
Giles, Francis J., Jörge E. Cortes, Deborah A. Thomas, et al.. (2002). Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.. PubMed. 8(7). 2134–41. 27 indexed citations
9.
Sharma, Sunil, Nancy E. Kemeny, Gary K. Schwartz, et al.. (2001). Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.. PubMed. 7(12). 3963–70. 16 indexed citations
10.
Rowinsky, Eric K., Thomas R. Johnson, Charles E. Geyer, et al.. (2000). DX-8951f, a Hexacyclic Camptothecin Analog, on a Daily-Times-Five Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies. Journal of Clinical Oncology. 18(17). 3151–3163. 37 indexed citations
11.
Lawrence, Richard, Elżbieta Izbicka, Robert L. De Jager, et al.. (1999). Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells. Anti-Cancer Drugs. 10(7). 655–662. 16 indexed citations
12.
Güleç, Seza A., Aldo N. Serafini, Frederick L. Moffat, et al.. (1995). Radioimmunoscintigraphy of colorectal carcinoma using technetium-99m-labeled, totally human monoclonal antibody 88BV59H21-2.. PubMed. 55(23 Suppl). 5774s–5776s. 9 indexed citations
13.
Jager, Robert L. De, et al.. (1978). Clinical trial of nafoxidine in advanced breast cancer. Medical and Pediatric Oncology. 4(2). 123–126. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kevie Feit Breakdown of academic impact, for papers by Henry J. Durivage Breakdown of academic impact, for papers by Federico Castiglione Breakdown of academic impact, for papers by G. Stathopoulos Breakdown of academic impact, for papers by Jianling Zou Breakdown of academic impact, for papers by Yasuhiro Arakawa Breakdown of academic impact, for papers by Monica Capozzi Breakdown of academic impact, for papers by C. Louvet Breakdown of academic impact, for papers by Eleonora Zaccarelli
Rankless by CCL
2026